Several clinical features can be accurate in differentiating between familial chylomicronemia syndrome and severe hypertriglyceridemia.
One-third of patients with diabetes and HTG overall and approximately 40% of statin users were found to be at high long-term cardiovascular risk.
Initiation of statin therapy during childhood in patients with familial hypercholesterolemia slows the progression of CIMT and reduces the risk for CVD over 20 years.
Compared with usual care, a polypill regimen led to greater reductions in systolic blood pressure and low-density lipoprotein cholesterol level in socioeconomically vulnerable minority patients.
Inclisiran is a chemically synthesized small interfering RNA (siRNA) that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA.
Even with care in specialty clinics, LDL-C persists above target levels in more than half of patients with familial hypercholesterolemia.
Investigators examined whether pretreatment low-density lipoprotein cholesterol levels and aortic stenosis severity affect lipid-lowering therapy to decrease aortic valve replacement.
Researchers used using observational administrative claims data from the Optum Research Database to retrospectively examine the real-world effect of elevated triglyceride levels on cardiovascular outcomes and medical cost.
Investigators analyzed whether high LDL-C causally relates to risk for retinopathy, neuropathy, chronic kidney disease, and peripheral artery disease in the general population.
Researchers evaluated how feasible, safe, and effective evolocumab is at lowering low-density lipoprotein cholesterol when initiated in patients hospitalized with acute coronary syndrome.